AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Article Link
Collect
Submit Manuscript
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Research Article

Pulmonary administration of functionalized nanoparticles significantly reduces beta-amyloid in the brain of an Alzheimer's disease murine model

Giulio Sancini1,§, Roberta Dal Magro1,§( ), Francesca Ornaghi1,†, Claudia Balducci2, Gianluigi Forloni2, Marco Gobbi3, Mario Salmona3, Francesca Re1
Nanomedicine CenterSchool of Medicine and SurgeryUniversity of Milano-Bicocca, via Cadore 4820900Monza (MB), Italy
Department of NeuroscienceIRCCS-Istituto di Ricerche Farmacologiche Mario Negri, via La Masa 1920159Milano, Italy
Department of Biochemistry and Molecular PharmacologyIRCCS-Istituto di Ricerche Farmacologiche Mario Negri, via La Masa 1920159Milano, Italy

§These authors contributed equally to this work.

†Present address: San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), Division of Regenerative Medicine, Stem Cells and Gene Therapy, IRCCS San Raffaele Scientific Institute, via Olgettina 60, 20132 Milano, Italy

Show Author Information

Abstract

Treatment options for Alzheimer's disease (AD) are limited because of the inability of drugs to cross the blood-brain barrier (BBB). A promising strategy to overcome this obstacle is the use of nanoparticles (NPs). Previously, we showed that intraperitoneal administration of liposomes functionalized with phosphatidic acid and an ApoE-derived peptide (mApoE-PA-LIP) reduces brain beta-amyloid (Aβ) burden and ameliorates impaired memory in AD mice. Here, we investigated lung administration as an alternative, non-invasive NP delivery route for reaching the brain. Our results show that mApoE-PA-LIP were able to cross the pulmonary epithelium ([14C]-PA permeability = 6.5 ± 2.0 × 10-6 cm/min) in vitro and reach the brain (up to 0.6 μg PA/g brain) following in vivo intratracheal instillations. Lung administration of mApoE-PA-LIP to AD mice significantly decreased total brain Aβ (-60%; p < 0.05) compared to untreated mice. These results suggest that pulmonary administration could be exploited for brain delivery of NPs designed for AD therapy.

Graphical Abstract

References

【1】
【1】
 
 
Nano Research
Pages 2190-2201

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Sancini G, Magro RD, Ornaghi F, et al. Pulmonary administration of functionalized nanoparticles significantly reduces beta-amyloid in the brain of an Alzheimer's disease murine model. Nano Research, 2016, 9(7): 2190-2201. https://doi.org/10.1007/s12274-016-1108-8

1147

Views

15

Crossref

N/A

Web of Science

17

Scopus

1

CSCD

Received: 01 March 2016
Revised: 18 April 2016
Accepted: 19 April 2016
Published: 20 May 2016
© Tsinghua University Press and Springer-Verlag Berlin Heidelberg 2016